AstraZeneca reported very strong commercial performance in the first nine months of 2025 with total revenue up 11% and core EPS up 15%, reiterated four‑year guidance for high single‑digit revenue ...
Executive Vice President, BioPharmaceuticals Business Unit - Ruud Dobber ...
AstraZeneca has seen major momentum in oncology in recent years. It got a big showcase at Europe's top cancer conference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results